| Methods |
4‐week single‐blind placebo run‐in; inclusion criteria= DBP 95‐114 mm Hg after run‐in; 4‐week double‐bind treatment at fixed dose; after 4 weeks (week 0‐4), patients with inadequate BP response had their doses doubled during the second 4 weeks (week 4‐8); hydrochlorothiazide 12.5 mg (in a single morning dose) was added during final 4 weeks (week 8‐12) |
| Participants |
All patients: n=18(10 males,8 females); mean age=52(12) years;
Cilazapril 2.5 mg: n=9; baseline sitting SBP=155(15) mm Hg, DBP=104(4) mm Hg, HR=77(8) bpm;
Placebo: n=9; baseline sitting SBP=152(15) mm Hg, DBP=100(4) mm Hg, HR=83(8) bpm |
| Interventions |
Cilazapril 2.5 mg once daily;
Placebo |
| Outcomes |
Trough sitting SBP/DBP using mercury sphygmomanometer;
Trough standing SBP/DBP using mercury sphygmomanometer;
Trough sitting HR;
Trough standing HR;
WDAE |
| Notes |
Used week 4 BP data only; BP change and SD of change not reported; endpoint BP and SD reported; imputed endpoint SD for SD of change; BP data from Table 1, p. 174; Jadad score=3; funding source= Hoffmann‐La Roche Ltd. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
